Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms

被引:54
作者
Cocuaud, C [1 ]
Rodier, MH [1 ]
Daniault, G [1 ]
Imbert, C [1 ]
机构
[1] CHU La Miletrie, Lab Parasitol & Mycol Med, F-86021 Poitiers, France
关键词
candidiasis; catheters; antifungals; metabolism; echinocandins;
D O I
10.1093/jac/dki269
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Candidiasis can be associated with the formation of biofilms on bioprosthetic surfaces and the intrinsic resistance of Candida albicans biofilms to the most commonly used antifungal agents has been demonstrated. In this study, we report on the antifungal activity of caspofungin at two different concentrations, on C. albicans and Candida parapsilosis biofilms with different ages of maturation. Methods: Fifteen strains of C. albicans (10 strains susceptible to fluconazole in vitro and five strains resistant to this antifungal agent) and six strains of C. parapsilosis (all were susceptible to fluconazole in vitro) were studied. The antifungal activity of caspofungin was assessed by looking for a significant inhibition of the metabolic activity of yeasts within biofilms. Biofilms of Candida were produced in vitro, on silicone catheters. Results: Caspofungin used at MIC did not modify the metabolic activity of C. albicans, whatever the maturation age of the biofilms. The same concentration of caspofungin significantly reduced the metabolism (P <= 0.001) of 25% (biofilms of 48 h) to 50% (biofilms of 2 h) of the C. parapsilosis yeasts. The use of a therapeutic concentration of caspofungin (2 mg/L) significantly decreased (P <= 0.001) the metabolism of all the strains of C. albicans and C. parapsilosis tested, independently of the biofilm maturation age. This potent antifungal activity of caspofungin on C. albicans biofilms was observed independently of the yeast susceptibility to fluconazole. Conclusions: This study demonstrated that caspofungin used at MIC was not sufficient to reduce C. albicans biofilms, but it suggested an activity on C. parapsilosis biofilms depending on their maturation age. This study also indicated that caspofungin used at 2 mg/L could be a good candidate in the prevention of candidiasis associated with silicone medical devices. Our results also suggested that fluconazole resistance of yeasts did not affect caspofungin activity.
引用
收藏
页码:507 / 512
页数:6
相关论文
共 28 条
  • [1] In vitro activity of caspofungin against Candida albicans biofilms
    Bachmann, SP
    VandeWalle, K
    Ramage, G
    Patterson, TF
    Wickes, BL
    Graybill, JR
    López-Ribot, JL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) : 3591 - 3596
  • [2] When to suspect fungal infection in neonates:: A clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia
    Benjamin, DK
    Ross, K
    McKinney, RE
    Benjamin, DK
    Auten, R
    Fisher, RG
    [J]. PEDIATRICS, 2000, 106 (04) : 712 - 718
  • [3] Cell wall and secreted proteins of Candida albicans:: Identification, function, and expression
    Chaffin, WL
    López-Ribot, JL
    Casanova, M
    Gozalbo, D
    Martinez, JP
    [J]. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1998, 62 (01) : 130 - +
  • [4] Biofilm formation by the fungal pathogen Candida albicans:: Development, architecture, and drug resistance
    Chandra, J
    Kuhn, DM
    Mukherjee, PK
    Hoyer, LL
    McCormick, T
    Ghannoum, MA
    [J]. JOURNAL OF BACTERIOLOGY, 2001, 183 (18) : 5385 - 5394
  • [5] Non-albicans shape Candida species isolated from plastic devices
    Dorko, E
    Kmeto'vá, M
    Marossy, A
    Dorko, F
    Molokácová, M
    [J]. MYCOPATHOLOGIA, 1999, 148 (03) : 117 - 122
  • [6] The measurement temperature:: an important factor relating physicochemical and adhesive properties of yeast cells to biomaterials
    Gallardo-Moreno, AM
    González-Martín, ML
    Pérez-Giraldo, C
    Bruque, JM
    Gómez-García, AC
    [J]. JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2004, 271 (02) : 351 - 358
  • [7] Caspofungin - a new therapeutic option for oropharyngeal candidiasis
    Garbino, J
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (03) : 187 - 189
  • [8] Imbert C, 2002, MED MYCOL, V40, P123, DOI 10.1080/mmy.40.2.123.129
  • [9] Imbert C, 2001, J MYCOL MED, V11, P14
  • [10] Fungal biofilms and drug resistance
    Jabra-Rizk, MA
    Falkler, WA
    Meiller, TF
    [J]. EMERGING INFECTIOUS DISEASES, 2004, 10 (01) : 14 - 19